Logotype for Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals (IONS) investor relations material

Ionis Pharmaceuticals Innovation Day 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Ionis Pharmaceuticals Inc
Innovation Day 2025 summary7 Oct, 2025

Strategic Vision and Growth Outlook

  • Focused on becoming a fully integrated, commercial-stage biotech, prioritizing wholly owned pipeline and independent launches in neurology and cardiometabolic diseases, with a steady cadence of independent and partnered medicine launches targeting both rare and prevalent diseases.

  • Achieved or exceeded all key milestones set six years ago, including building a robust pipeline, commercial organization, and expanding RNA-targeted drug discovery.

  • Advancing a high-value, innovative pipeline with multiple late-stage and recently approved medicines, including TRYNGOLZA, DAWNZERA, and Olezarsen.

  • Ongoing investment in technology platforms, including RNA-targeted medicines, siRNA, and delivery innovations to maintain leadership and expand therapeutic reach.

  • Clear path to sustained positive cash flow by 2028, supported by strong financial resources (~$2B cash), disciplined expense management, and efficient capital structure.

Key Product and Clinical Developments

  • TRYNGOLZA (olezarsen) approved for FCS, showing substantial triglyceride and pancreatitis reduction, strong early commercial uptake, and approved in the EU.

  • Olazarsen demonstrated up to 72% mean placebo-adjusted triglyceride reduction and 85% reduction in acute pancreatitis in SHTG, with sNDA filing planned by year-end and launch expected in the second half of next year.

  • DAWNZERA (donidalorsen) launched in the US for HAE, offering first RNA-targeted prophylactic with strong efficacy, tolerability, and convenient dosing; EU launch anticipated in 2026.

  • Zilganersen pivotal data for Alexander disease showed disease stabilization and robust safety, with NDA filing and first neurology launch planned for next year.

  • ION582 for Angelman syndrome showed positive long-term data and broad Phase III enrollment, targeting both pediatric and adult populations, with full enrollment expected in 2026.

Commercial and Financial Strategy

  • Commercial infrastructure built to support current and future launches, with omnichannel education reaching over 30,000 HCPs and strong payer dynamics.

  • FCS launch generated $19M in Q2 revenue, with full-year guidance of $75–80M; Donzara launch off to an encouraging start.

  • Olazarsen positioned as a potential blockbuster, targeting a million high-risk SHTG patients initially, with pricing and access strategy under development.

  • Financial discipline maintained, with $2B in cash, clear path to sustained positive cash flow by 2028, and peak annual revenue potential exceeding $5B from multiple products and royalties.

  • Multiple blockbuster opportunities in the pipeline, with independent and partner launches expected to generate over $5B in combined annual peak revenue.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Ionis Pharmaceuticals earnings date

Logotype for Ionis Pharmaceuticals Inc
Q3 202529 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Ionis Pharmaceuticals earnings date

Logotype for Ionis Pharmaceuticals Inc
Q3 202529 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Ionis Pharmaceuticals Inc. discovers and develops RNA-targeted therapeutics. It applies antisense technology platforms to develop treatments for a range of genetic and rare diseases. The company is headquartered in Carlsbad, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage